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INTRODUCTION
Mesenchymal stem cells (MSCs) are capable of self-renew-
al and differentiation into lineages of mesenchymal tissues,
including bone, cartilage, fat, tendon, muscle, and hematopoi-
etic supporting stroma (1, 2). While the most abundant sour-
ce of MSCs is the bone marrow (BM), MSCs can be obtained
from other tissues such as peripheral blood, periosteum, mus-
cle, adipose tissue, and the connective tissue of human adults
(3).
MSCs from cord blood (CB) and the placenta may serve
as alternative sources to adult MSCs. These potential alter-
native sources are important for a number of reasons, includ-
ing the significant reduction in the number of MSCs with
age and the high risk of viral contamination in the BM as
well as the painful procedure required for the collection of
BM MSCs. CB and placenta are potential alternative sources
of MSCs; they are routinely discarded after delivery, and the
ethical concerns and viral contamination issues are less of a
problem. Several investigators have successfully isolated, ex-
panded, and characterized the MSCs from CB and the pla-
centa, and have evaluated their potential for differentiation
into osteogenic, chondrogenic or adipogenic lineages (4-6).
In animal models, MSCs can be induced to circulate into
peripheral blood under certain conditions, such as hypoxia
(7). The chemotactic signals that guide MSCs to appropriate
microenvironments or induce their circulation have yet to be
identified. In hematopoietic stem cells (HSC), the predomi-
nant role of stromal derived factor-1 (SDF-1) and its receptor
CXCR-4 is now well established (8). Some soluble factors
have recently been reported to exert chemotactic effects on
BM MSCs, including chemokines (9) and growth factors (10),
however, their respective physiological relevance remains un-
clear. An improved knowledge of the chemotactic factors that
affect MSCs would be of clinical interest since modulation
of their activity could affect not only engraftment efficiency
at damaged sites but also their mobilization into peripheral
blood. Ponte et al. (11) showed that, in contrast to what is
known about HSCs, a wide range of soluble factors exert sig-
nificant chemotactic activity on MSCs and some growth fac-
tors are better chemoattractants than chemokines. Inflamma-
tory cytokines such as tumor necrosis factor α(TNFα ) can
increase the sensitivity of MSCs to chemokines.
In this study, we characterized and compared the cytokine
expression of BM-MSCs, CB-MSCs, and placental MSCs using
a commercial human cytokine protein array assay to identi-
fy the protein expression profiles of the MSCs from BM, CB
and the placenta. This study focused on the cytokines associ-
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Comparison of Cytokine Expression in Mesenchymal Stem Cells from
Human Placenta, Cord Blood, and Bone Marrow
Mesenchymal stem cells (MSCs) are capable of self-renewal and differentiation into
lineages of mesenchymal tissues that are currently under investigation for a variety
of therapeutic applications. The purpose of this study was to compare cytokine gene
expression in MSCs from human placenta, cord blood (CB) and bone marrow (BM).
The cytokine expression profiles of MSCs from BM, CB and placenta (amnion, decidua)
were compared by proteome profiler array analysis. The cytokines that were expre-
ssed differently, in each type of MSC, were analyzed by real-time PCR. We evalu-
ated 36 cytokines. Most types of MSCs had a common expression pattern includ-
ing MIF (GIF, DER6), IL-8 (CXCL8), Serpin E1 (PAI-1), GROα(CXCL1), and IL-6.
MCP-1, however, was expressed in both the MSCs from the BM and the amnion.
sICAM-1 was expressed in both the amnion and decidua MSCs. SDF-1 was ex-
pressed only in the BM MSCs. Real-time PCR demonstrated the expression of the
cytokines in each of the MSCs. The MSCs from bone marrow, placenta (amnion
and decidua) and cord blood expressed the cytokines differently. These results sug-
gest that cytokine induction and signal transduction are different in MSCs from dif-
ferent tissues.
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Accepted : 9 January 2009ated with the monocyte chemotactic protein-1 (MCP-1), sol-
uble intercellular adhesion molecule-1 (sICAM-1) and SDF-1.
MATERIALS AND METHODS
Isolation of mesenchymal stem cells 
MSCs from human BM, CB, and the amnion and decidua
of the placenta were studied. The BM MSCs, in the first pas-
sage, were obtained from the Department of Orthopedic Sur-
gery. The CB MSCs, in the first passage, were obtained from
MEDIPOST Co. (Seoul, Korea). The human placentas (from
clinically normal pregnancies, gestational age, 34-41 weeks)
were obtained after vaginal deliveries or caesarean section bir-
ths. All tissues were obtained with the approval of the Korea
University Medical Center Institutional Review Board. The
amnion and decidua were mechanically peeled from the pla-
centa, and washed with phosphate-buffered saline (PBS) sev-
eral times to remove excessive blood. The tissues were incu-
bated with 1 mg/mL type I collagenase for three hours after
being cut into small pieces (1 cm3) with scissors. The mononu-
clear cells in the collagenase were collected. After centrifuga-
tion, the cells were washed with PBS and resuspended in an
α -minimum essential medium (MEM, Gibco BRL, Life Tech-
nologies, Merelbeke, Belgium) supplemented with 10% fetal
bovine serum, and 10 ng/mL basic fibroblast growth factor
(bFGF). The cells were seeded into a T75 flask. The cultures
were maintained at 37℃ in a humidified atmosphere with
5% CO2. Three to five days after initiating the incubation,
the small digested residues were removed and the culture was
continued. The medium was replaced one to two times every
week, every third to fourth day.
Flow cytometry analysis
The specific surface antigens of MSCs in the cultures of pas-
sage two to four were characterized by flow cytometry anal-
ysis. The cells in culture were trypsinized and stained with
fluorescein isothiocyanate (FITC)- or phycoerythrin (PE)-
conjugated antibodies against CD29, CD31, CD34, CD44,
CD45, HLA-DR, CD73, CD90, and CD105 (Immunotech,
Marseille, MN, U.S.A.). Thereafter, the cells were analyzed
using a Becton Dickinson flow cytometer (Becton Dickin-
son, San Jose, CA, U.S.A.).
Adipogenic induction
The medium was replaced with adipocyte induction medi-
um or control (stromal) medium, as previously described (12).
The induction medium contained a low glucose Dulbecco’s
Modified Eagle’s Medium (LG-DMEM) with 10% FBS, 200
μ M indomethacin, 1 μ g/mL insulin, 1 mM dexamethasone,
0.5 mM isobutylmethylxanthine (IBMX), 100 U/mL peni-
cillin, 100 mg/mL streptomycin, and 0.25 mg/mL ampho-
tericin B. After 3 days, the medium was changed to adipocyte
maintenance medium that was identical to the induction me-
dia but without IBMX. The cells were maintained in culture
for 14 days, with 90% of the maintenance media replaced
every 3 days.
Osteogenic induction
The medium was replaced with osteoblast induction medi-
um or control (stromal) medium, as previously described (12).
Osteoblast induction medium contained DMEM (low glu-
cose) with 10% fetal bovine serum, 10 mM β -glycerophos-
phate, 0.15 mM ascorbate-2-phosphate, 10 nM 1,25-(OH)
2 vitamin D3, 10 nM dexamethasone, 100 U/mL penicillin,
100 mg/mL streptomycin, and 0.25 mg/mL amphotericin B.
The cells were maintained in culture for 21 to 28 days, with
90% of the media replaced every 3 days.
The assessment of cell viability and cell number in cultures
The cultured cells were detached from the culture dishes
with 0.05% trypsin-EDTA (Gibco BRL, Life Technologies)
at 72 hr of culture under different culture conditions. The
cells were stained with trypan blue (Gibco BRL, Life Tech-
nologies), and the viable cells that did not stain were count-
ed on a hemocytometer.
The focused protein array
The culture media were collected at different incubation
periods. All focused protein array analyses were performed
according to the manufacturer’s instructions. Positive controls
were located in the upper left-hand corner (two spots), lower
left-hand corner (two spots) and lower right-hand corner (two
spots) of each array kit. Each culture media was measured
using the human cytokine array panel A (proteome profil-
erTM) (R&D Systems, Minneapolis, MN, U.S.A.). Horseradish
peroxidase substrate (Bio-Rad, Hercules, CA, U.S.A.) was
used to detect protein expression and data were captured by
exposure to Kodak BioMax Light film. Arrays were scanned
into a computer and optical density measurements were ob-
tained with the Image Pro Plus v 5.1 software (Media Cyber-
netics, Silver Spring, MD, U.S.A.).
Total RNA isolation and reverse-transcriptase reaction
RNA extraction and purification were performed using an
RNeasy mini kit as described in the manufacturer’s protocol
(Qiagen, Valencia, CA, U.S.A.). The concentration of RNA
was measured using a spectrophotometer (DU
�530, Beck-
man, Fullerton, CA, U.S.A.), and the RNA quality was con-
firmed by agarose gels. A total RNA sample (2 μ g/sample)
was used with 20 μ L of sample to generate cDNA using the
SuperScriptTM III First-Strand Synthesis System RT-PCR kit
(Invitrogen, Milan, Italy). RNA was reverse-transcribed un-
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mix, 10×RT buffer, 0.1 M DTT, 200 U of SuperScriptTM
III (Invitrogen), 40 U of RNaseOut, and 50 μ M oligo d(T)
primers in a final volume of 20 μ L. The reaction was run at
65℃for 5 min and at 50℃for 50 min, and then the enzyme
was heat inactivated at 85℃for 5 min. For the real-time PCR
reaction, 4 μ L of reaction product were used.
Real-time PCR analysis
The proteome profiler results showed that there was dif-
ferent cytokine expression for each type of MSC including
sICAM-1 (CD54), MCP-1 (CCL2), and SDF-1 (CXCL12). A
real-time PCR analysis was used to quantify the sICAM-1
(CD54), MCP-1 (CCL2), and SDF-1 (CXCL12) transcripts.
Their expression was normalized using the GAPDH house-
keeping gene product as an endogenous reference. The primers
and probes were designed for human sICAM-1, MCP-1, and
SDF-1 using Primer Express 2.0 (Applied Biosystems, Fos-
ter City, CA, U.S.A.). sICAM-1 (CD54), MCP-1 (CCL2), and
SDF-1 (CXCL12) mRNA levels were quantified using Taq-
Man Real-Time PCR with an ABI 7700 system (Applied
Biosystems). Gene-specific probes and primer pairs for ICAM-
1 (Assays-on-Demand, Hs00164932_m1; Applied Biosys-
tems), MCP-1 (Assays-on-Demand, Hs00234140_m1; Ap-
plied Biosystems), and SDF-1 (Assays-on-Demand, Hs00-
171022_m1; Applied Biosystems) were used. For each probe/
primer set, a standard curve was generated, which was con-
firmed to increase linearly with increasing amounts of cDNA.
The amplification conditions were 2 min at 50℃, 10 min
at 95℃, and a two-step cycle of 95℃ for 15 sec, and 60℃
for 60 sec for a total of 45 cycles.
Western blotting
Protein lysates were obtained with a buffer containing 50
mM HEPES (pH 7.5), 150 mM NaCl, 1.5 mM MgCl2, 1 mM
EDTA, 10% glycerol, 1% Triton X-100, and a mixture of
protease inhibitors (aprotinin, PMSF, and sodium orthovana-
date). Equal amounts of total protein were resolved on a 12%
SDS-polyacrylamide gel. The proteins were transferred to a
nitrocellulose membrane. After blocking (TBS, 0.1% Tween-
20) at 4℃ overnight, the membranes were incubated with
primary antibodies of anti-mouse SDF-1, anti-mouse MCP-
1, and anti-mouse sICAM-1 (R & D systems); all monoclonal
antibodies were used at a dilution of 1:1,000 for 2 hr followed
by incubation with secondary antibodies linked to HRP (Bio-
Rad) and anti-rabbit GAPDH (dilution 1:2,000, Assay De-
signs, Inc., Ann Arbor Michigan, U.S.A.). Immunoreactive
proteins were visualized by chemiluminescence using Super-
Signal West Dura Extended Duration Substrate (Pierce Che-
mical Co., Rockford, IL, U.S.A.). Fujifilm Luminescent Image
Analyzer LAS-3000, with a charged-coupled device camera
(Science Imaging Scandinavia AB), was used for imaging. 
Statistics
Data are presented as the mean±SD. Data were analyzed
with SPSS statistical software, version 12.0 (SPSS Inc, Chica-
go, IL, U.S.A.). The differences in cytokine concentrations
among four groups of subjects were analyzed by the Kruskal-
Wallis and Mann-Whitney tests. A probability of 0.05 was
considered significant.
RESULTS
Isolation, culture, flow cytometry analysis and differentiation
of placental MSCs
After enzyme digestion of the placental amnion and decid-
ua, the cells were seeded into T-75 cell culture flasks at a con-
fluence of 80%. The adherent cells with fibroblastic morphol-
ogy were analyzed. The cells formed a monolayer of homoge-
nous bipolar spindle-like cells with a whirlpool-like array in
two to three days (Fig. 1), and these adherent cells could be
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Fig. 1. Appearance and growth of fibroblastoid cells or placental mesenchymal stem cells at passage 1 on day 11.
Amnion #11 Decidua #11 10.0 μ m 10.0 μ mreadily expanded in vitro by successive cycles of trypsinization,
seeding and culture every three days for three passages with-
out visible morphologic change. The MSCs from term placen-
tal amnion and decidua were successfully isolated. We found
no correlation between gestational age and the successful estab-
lishment of MSC cultures from the amnion and decidua.
We examined the surface marker profile of the amnion and
decidua derived cell lines using fluorescence activated cell
sorting (FACS). The phenotype of the MSCs derived from
amnion was similar to that of MSCs derived from the decid-
ua. These cells were positive for CD29, CD44, and CD73 but
were negative for CD31, CD34, CD45, and HLA-DR (Fig.
2). CD 105 was positive in amnion MSC whereas CD 90 was
positive in the decidua.
To estimate their potential to differentiate into several tis-
sue lineages, the MSCs from the amnion and decidua were
cultured in adipogenic, osteogenic, myogenic, and neurogenic
medium. At the end of the induction period, the cells were
differentiated into their respective tissues. The confirmation
of differentiation was made by Oil Red O for adipogenic dif-
ferentiation (Fig. 3A), Alizarin Red S staining for osteogenic
differentiation (Fig. 3B), respectively. Culture expanded cells
from the amnion and decidua were all able to differentiate
into adipogenic and osteogenic lineages.
Cytokine array analysis
The conditioned medium, after 3-4 days of culture of the
MSCs from CB, BM, and placenta (amnion, chorion), was
assayed using the human cytokine array panel A (R & D sys-
tems) according to the manufacturer’s instructions. We ana-
lyzed 36 cytokines at a time. The 36 cytokines included: C5a,
CD40 Ligand, G-CSF, GM-CSF, GROα , I-309, sICAM-1,
IFN-γ , IL-1α , IL-1β , IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-8, IL-
10, IL-12p70, IL-13, IL-16, IL-17, IL-17E, IL-23, IL-27, IL-
32α , IP-10, I-TAC, MCP-1, MIF, MIP-1α , MIP-1β , Serpin
E1, RANTES, SDF-1, TNFα , and sTREM-1.
CB MSCs secreted: MIF (GIF, DER6), IL-8 (CXCL8), Ser-
pin E1 (PAI-1), GROα(CXCL1), and IL-6. BM MSCs secret-
ed: MIF (GIF, DER6), IL-8, Serpin E1 (PAI-1), GROα(CX-
CL1), IL-6, MCP-1 (CCL2), and SDF-1 (CXCL12). Amnion
MSCs secreted: GROα(CXCL1), sICAM-1 (CD54), IL-6,
IL-8, MCP-1 (CCL2), MIF (GIF, DER6), and serpin E1. De-
cidua MSCs secreted: GROα(CXCL1), sICAM-1 (CD54),
IL-6, IL-8, MIF (GIF, DER6), and Serpin E1.
Each of the MSCs expressed: MIF (GIF, DER6), IL-8 (CX-
CL8), Serpin E1 (PAI-1), GROα(CXCL1), and IL-6. How-
ever, MCP-1 (CCL2) was expressed only in the BM MSCs
and amnion MSCs. sICAM-1 (CD54) was expressed in both
the amnion and decidua MSCs. SDF-1 was expressed in only
the BM MSCs (Fig. 4A). The relative expression level of the
cytokines was calculated. The MCP-1 expression in the BM
MSCs was higher than the expression in the amnion MSCs,
whereas the expression of IL-6 in the CB MSCs was compar-
atively lower. GROαexpression was higher in both the BM
MSCs and amnion MSCs compared to the CB MSCs and the
amnion MSCs (Fig. 4B).
The Detection of SDF-1 (CXCL12), MCP-1 (CCL2) and
sICAM-1 (CD54) in each of the tissue-MSCs by RT-PCR
SDF-1 (CXCL12), MCP-1 (CCL2) and sICAM-1 (CD54) ex-
pression of human MSCs derived from three different origins
were determined at the level of gene expression (n=8). Real
time RT-PCR demonstrated that the human MSCs derived
from the three different origins express cytokines different-
ly. The level of mRNA was quantified and compared with a
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Fig. 2. Immunophenotypic results of passage 3 MSCs by FACS analysis. (A) MSC from amnion (B) MSC from decidua. Representative
histogram (black line). The respective isotype control is shown as gray.
CD 29 CD 31 CD 34 CD 44 CD 45 CD 73 CD 90 CD 105 HLA DR
CD 29 CD 31 CD 34 CD 44 CD 45 CD 73 CD 90 CD 105 HLA DR B
A
Fig. 3. Differentiation potential of MSCs obtained from the amnion
and decidua. (A) Adipogenic differentiation of MSC shown by Oil
red O staining of adipocytes (×200). (B) Osteogenic differentiation
of MSC shown by Alizarin red S (×200). (A, amnion; D, decidua).
AD
B
A
ADhousekeeping gene (GAPDH). The higher expression of SDF-
1 (CXCL 12) in BM MSCs was confirmed by RT-PCR (P=
0.006). However, the RT-PCR did not confirm differences
for the gene encoding MCP-1 (CCL2) among the four MSCs
(P=0.252) derived from different tissues. The gene encoding
sICAM-1 was found to be expressed at a higher level in the
decidua MSCs (P=0.002) (Fig. 5). SDF-1, MCP-1, and sICAM-
1 expression was confirmed by Western blot analysis in the
amnion and decidua MSCs (n=2) (Fig. 6).
DISCUSSION
Mesenchymal stem cells are thought to have great thera-
peutic potential due to their capacity for self-renewal and
multilineage differentiation (2, 13). They support hemato-
poiesis and enhance the engraftment of hematopoietic stem
cells after co-transplantation (14, 15). Experimental and clin-
ical data have demonstrated an immunoregulatory function
of BM-derived MSCs (BM MSC) that may contribute to the
reduction of graft-versus-host disease following hematopoi-
etic stem cell transplantation (16, 17). Currently, the BM rep-
resents the major source of MSCs for cell therapy. However,
aspiration of BM involves invasive procedures, and the fre-
quency and differentiation potential of BM MSC decrease
significantly with age (18). The search for alternative sources
of MSCs, therefore, is of significant value. It has been report-
ed that MSCs could be isolated from various tissues includ-
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Fig. 4. (A) The cytokine expression in each of the MSCs using the proteome profiler. (B) Quantification of cytokine optical density. Measure-
ments were obtained with the Image Pro Plus v 5.1 software (Media Cybernetics, Silver Spring, MD, U.S.A.). 
CB, cord blood; BM, bone marrow; AM, amnion; DE, decidua MSCs; MSC, mesenchymal stem cells.
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DE MSC A Bing periosteum, trabecular bone, adipose tissue, synovium,
skeletal muscle, deciduous teeth, fetal pancreas, lung, liver,
amniotic fluid, CB, and placental tissues (19, 20). Among
these sources, CB and the placenta may be ideal sources due
to their accessibility, painless donor procurement, promising
sources for autologous cell therapy, and lower risk of viral con-
tamination.
We isolated MSCs from the amnion and decidua. After iso-
lation and culture, under specified conditions, typical MSC-
like cells similar to the cells from the amnion and decidua
were identified. These cells were characterized by the same
shape and size, and the same monolayer appearance. In addi-
tion, the cells expressed CD29, CD31, CD34, CD44, CD45,
HLA-DR, CD73, CD90, and CD105 by cytofluorimetry.
Expression of the main marker genes of MSCs (CD29, CD44
and CD73) were positive and similar in all of the MSCs stud-
ied. (Data for BM MSCs and CB MSCs: not shown). Expres-
sion of CD31, CD34, CD45, and HLA-DR were negative.
CD90 was positive only in the decidua-derived MSCs, where-
as CD105 was positive only in the amnion-derived MSCs.
The identity of MSCs from different sources has not been pre-
viously proven. The results of this study of placenta-derived
MSCs may provide an attractive and rich source of MSCs.
Initially, cytokine analysis was performed with the pro-
teome profilerTM to determine which cyotokines were expre-
ssed differently. Then, the cytokines were confirmed by PCR
analysis. There was some discrepancy between the proteome
profilerTM and the PCR analysis. For example, there was no
significant difference in the expression of the gene encoding
MCP-1 (CCL2) among the four differently derived MSCs by
the PCR analysis. However, by the proteome profilerTM anal-
ysis, the amnion MSCs and BM MSCs were found to secrete
MCP-1, whereas the CB MSCs and decidua MSCs did not
secrete MCP-1. The gene encoding sICAM-1 was found to be
expressed at a higher level in the decidua MSCs. The prote-
ome profiler analysis, however, showed that the concentration
of sICAM-1 was higher in the amnion MSCs compared to decid-
ua MSCs. The manufacturing company recommended that
the proteome profilerTM be used as a screening tool. Therefore,
we depended on the results of the PCR analysis and Western
blot to confirm the expression of SDF-1, MCP-1, and sICAM-1
in the MSCs from the amnion and the decidua.
Potian et al. (21) recently analyzed the cytokine profile of
BM MSCs using the protein array technique. IL-6, IL-8, MCP-
1, RANTES, GROα , INFγ , IL-1α , TGFβ , GM-CSF, angio-
genin, and oncostatin M were constitutively expressed, and
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Fig. 5. The quantitative expression of SDF-1, MCP-1 and sICAM-1
in each of the mesenchymal stem cells. The mRNA levels were
quantified using TaqMan Real-Time PCR with an ABI 7700 sys-
tem (Applied Biosystems). The GAPDH housekeeping gene prod-
uct was used as an endogenous reference. (A) SDF-1, (B) MCP-
1, (C) sICAM-1. 
*Statistically significant difference (P<0.05).
SDF-1, stromal derived factor-1; MCP-1, monocyte chemotactic
protein-1; sICAM-1, intracellular adhesion molecule.
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Fig. 6. SDF-1, MCP-1 and sICAM-1 expression profile by Western
blot analysis in amnion-derived MSC and decidua-derived MSC.
AM MSC, amnion-derived MSC; DE MSC, decidua-derived MSC.MIP-1α , IL-2, IL-4, IL-10, IL-12, and IL-13 were not ex-
pressed by the BM MSCs. The results of this study showed
that the cytokine profile of the BM MSCs was very similar
to that of the CB MSCs, with the exception that the CB MSCs
expressed IL-12 but not G-CSF under serum-free conditions.
Haynesworth et al. (22) reported that constitutively expressed
cytokines in the growth phase include: IL-6, G-CSF, SCF, not
detected in the growth medium of human BM derived MSCs.
Both MSCs from the BM and CB abundantly produced IL-
6, IL-8, and MCP-1.
The role that chemokines and their receptors play in the
targeting of leukocytes to areas of inflammation, infection,
or injury has been well characterized (23). As chemokine recep-
tors are expressed on the cell surface of MSCs, and their stim-
ulation has been shown to induce cell migration, it seems
likely that they play a similar role in directing MSCs. MSCs
have been shown to express a variety of chemokine receptors.
The reported chemokine receptors of MSCs, however, have
been inconsistent under similar isolation and culture condi-
tions. This might be due to the heterogeneous nature of a
typical MSC population that obscures the detection of a dis-
tinct receptor repertoire.
Our study findings showed that SDF-1 (CXCL12) was more
highly expressed in the BM MSCs. SDF-1 is a small cytokine
belonging to the chemokine family that is officially designat-
ed CXCL12. CXCL12 is strongly chemotactic for lympho-
cytes and is, therefore, an important hematopoietic growth
factors for these cells (24-26). During embryogenesis it directs
the migration of hematopoietic cells from the fetal liver to
the BM. The receptor for this chemokine is CXCR4. This
CXCL12-CXCR 4 interaction used to be considered exclu-
sive, but recently it has been suggested that CXCL12 is also
bound by the CXCR7 receptor (27, 28). SDF-1 could aug-
ment the mobilization, migration, recruitment, and entrap-
ment of MSCs. SDF-1-CXCR4 interactions mediate the hom-
ing of MSCs. This suggests that SDF-1 plays an important
role in the mobilization and homing of BM MSCs, although
the signals required for this process have not been fully des-
cribed.
The cytokine expression profile of placental MSCs remains
poorly documented. We compared the cytokine expression
of BM MSCs, CB MSCs, amnion MSCs, and decidua MSCs
focusing on SDF-1 (CXCL12), MCP-1 (CCL2), and sICAM-
1 based on the protein array assay. In this study, sICAM-1 was
more highly expressed in decidua MSCs compared to the BM
MSCs, CB MSCs and amnion MSCs. sICAM-1 represents a cir-
culating form of ICAM-1 that is constitutively expressed or is
inducible on the cell surface of different cell lines (29). sICAM-
1 is a type of intercellular adhesion molecule continuously
present in low concentrations in the membranes of leukocytes
and endothelial cells. Upon cytokine stimulation, the concen-
trations of this molecule greatly increase. ICAM-1 can be in-
duced by interleukin-1 (IL-1) and TNFα , and is expressed by
the vascular endothelium, macrophages and lymphocytes (30).
Although amnion MSCs and decidua MSCs are derived from
the placenta, expression of sICAM-1 was found to be signif-
icantly lower in the amnion MSCs. Cytokine induction and
signal transduction may be different in the amnion MSCs
and the decidua MSCs. sICAM-1 is thought to play a more
important role in the decidua MSCs than in the amnion MSCs
with regard to cell recruitment. There was no significant dif-
ference in the expression of MCP-1 among the BM MSCs,
CB MSCs, amnion MSCs, and the decidua MSCs.
In addition to their role in mediating cell migration, che-
mokines may also play important autocrine and paracrine
roles. CXCL12 promotes the growth, survival, and develop-
ment of MSCs (31). MSCs are known to be able to synthesize
this chemokine, which may act in an autocrine manner via
CXCR4. Chemokines are also recognized as primary induc-
ers of integrin up-regulation following their interaction with
their cell surface receptors and various downstream signaling
events.
Integrins are known to mediate the firm adhesion of leuko-
cytes to endothelial cells and play an important role in their
transendothelial migration. It is likely that they play a sim-
ilar role for the MSCs. MSCs are known to express various
integrin molecules and their roles have begun to be elucidat-
ed. Pittenger et al. (2) reported the first study of integrin ex-
pression of MSCs and noted the presence of α 1, α 2, α 3 aα , α ν ,
β 1, β 3, and β 4 along with the other adhesion molecules IC-
AM-1, ICAM-3, VCAM-1, ALCAM, and endoglin (CD105).
The results of the present study provide the characteriza-
tion of cytokine expression of the MSCs from the BM, CB,
amnion, and decidua. The cytokines play a role in migration
of MSCs. The cytokine induction and signal transduction are
important for migration of the MSCs. The characteristics of
cytokine expression in MSCs derived from different tissues help
with the understanding of the mechanisms of MSC migra-
tion. Further studies are required to better understand the
interactions of these cytokines.
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